Type 1 Diabetes

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin¹.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® lowers blood glucose levels evenly over a long period of time. It therefore only needs to be administered once a day.

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo^® is available in two prefilled pens. See how Toujeo^® is administrated In six simple steps and watch instructional video.

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.